Unknown

Dataset Information

0

Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.


ABSTRACT: BACKGROUND:Induction of HIV-1-specific CD4(+) T-cell responses by therapeutic vaccination represents an attractive intervention to potentially increase immune control of HIV-1. METHODS:We performed a double-blinded, randomized, placebo-controlled clinical trial to determine the safety and immunogenicity of GlaxoSmithKline Biologicals' HIV-1 gp120/NefTat subunit protein vaccine formulated with the AS02(A) Adjuvant System in subjects with well-controlled chronic HIV-1 infection on highly active antiretroviral therapy. Ten individuals received the vaccine; whereas adjuvant alone or placebo was given to 5 subjects each. Immunogenicity was monitored by intracellular cytokine flow cytometry and carboxyfluorescein succinimidyl ester-based proliferation assays. RESULTS:The vaccine was well tolerated with no related serious adverse events. Vaccine recipients had significantly stronger gp120-specific CD4(+) T-cell responses which persisted until week 48 and greater gp120-specific CD4(+) T-cell proliferation activity as compared with controls. In the vaccine group, the number of participants who demonstrated positive responses for both gp120-specific CD4(+) T-cell interleukin-2 production and gp120-specific CD8(+) T-cell proliferation were significantly higher at week 6. CONCLUSIONS:The gp120/NefTat/AS02(A) vaccine induced strong gp120-specific CD4(+) T-cell responses and a higher number of vaccinees developed both HIV-1-specific CD4(+) T-cell responses and CD8(+) T-cell proliferation. The induction of these responses may be important in enhancing immune-mediated viral control.

SUBMITTER: Lichterfeld M 

PROVIDER: S-EPMC3241906 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.

Lichterfeld Mathias M   Gandhi Rajesh T RT   Simmons Rachel P RP   Flynn Theresa T   Sbrolla Amy A   Yu Xu G XG   Basgoz Nesli N   Mui Stanley S   Williams Katie K   Streeck Hendrik H   Burgett-Yandow Nicole N   Roy Gilbert G   Janssens Michel M   Pedneault Louise L   Vandepapelière Pierre P   Koutsoukos Marguerite M   Demoitié Marie-Ange MA   Bourguignon Patricia P   McNally Lisa L   Voss Gerald G   Altfeld Marcus M  

Journal of acquired immune deficiency syndromes (1999) 20120101 1


<h4>Background</h4>Induction of HIV-1-specific CD4(+) T-cell responses by therapeutic vaccination represents an attractive intervention to potentially increase immune control of HIV-1.<h4>Methods</h4>We performed a double-blinded, randomized, placebo-controlled clinical trial to determine the safety and immunogenicity of GlaxoSmithKline Biologicals' HIV-1 gp120/NefTat subunit protein vaccine formulated with the AS02(A) Adjuvant System in subjects with well-controlled chronic HIV-1 infection on h  ...[more]

Similar Datasets

| S-EPMC4372395 | biostudies-literature
| S-EPMC4889535 | biostudies-other
| S-EPMC8139695 | biostudies-literature
| S-EPMC3080892 | biostudies-literature
| S-EPMC4301108 | biostudies-literature
2016-03-07 | GSE17606 | GEO
| S-EPMC5007213 | biostudies-literature
| S-EPMC4546876 | biostudies-literature
| S-EPMC5028901 | biostudies-other
| S-EPMC5035742 | biostudies-literature